| Description | CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production. |
| In vitro | CL097 (0, 0.5, 2.5, 5, and 10 μg/mL) induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils[1]. CL097 (0.1 μM) induces activation of NF-κB in TLR7-transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells[3]. |
| In vivo | 在NOD小鼠中，CL097（5 mg/kg，皮下注射）对目标肽造成了约25%的适度特异性溶解。然而，将CL097与CD40激动剂（10 mg/kg，腹腔注射）联合治疗后，与单独使用CL097相比，IGRP-肽包被靶标的特异性溶解增加了约两倍[2]。 |
| Synonyms | CL097 |
| molecular weight | 242.28 |
| Molecular formula | C13H14N4O |
| CAS | 1026249-18-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 95 mg/mL (392.11 mM), Sonication is recommended. |
| References | 1. Karama Makni-Maalej, et al. The TLR7/8 agonist CL097 primes N-formyl-methionyl-leucyl-phenylalanine-stimulated NADPH oxidase activation in human neutrophils: critical role of p47phox phosphorylation and the proline isomerase Pin1. J Immunol. 2012 Nov 1;189(9):4657-65. 2. A S Lee, et al. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Diabetologia. 2011 Jun;54(6):1407-16. 3. Cindy Patinote, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238. |